Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2–P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach

The SARS-CoV-2 main protease (M(pro)) is an attractive target towards discovery of drugs to treat COVID-19 because of its key role in virus replication. The atomic structure of M(pro) in complex with an α-ketoamide inhibitor (Lig13b) is available (PDB ID:6Y2G). Using 6Y2G and the prior knowledge tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Achilonu, Ikechukwu, Iwuchukwu, Emmanuel Amarachi, Achilonu, Okechinyere Juliet, Fernandes, Manuel Antonio, Sayed, Yasien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Topical Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462840/
https://www.ncbi.nlm.nih.gov/pubmed/32920239
http://dx.doi.org/10.1016/j.jmgm.2020.107730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462840/
https://www.ncbi.nlm.nih.gov/pubmed/32920239
http://dx.doi.org/10.1016/j.jmgm.2020.107730

Ejemplares similares